Browsing: mRNA

The FDA has recently approved Moderna’s mRNA flu vaccine. The vaccine, known as mFLUSIVA (mRNA-1010), is designed to protect adults ages 50 years and older against seasonal flu. It is the first mRNA-based flu vaccine, using similar technology as the mRNA COVID-19 vaccine

Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc.(NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win

Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much as 160 percent

The Food and Drug Administration (FDA) has approved mFlusiva®, the first mRNA-based influenza vaccine, for adults aged 50 years and older. For persons aged 65 years and older, the vaccine received accelerated approval based on immune responses; continued approval in this age group is contingent upon verification and description of clinical benefit in a confirmatory…

The Food and Drug Administration on Wednesday approved the U.S.’ first flu shot that uses mRNA technology: mFlusiva, from drugmaker Moderna

Drawing together evidence from laboratory research, clinical trials and real-world studies, the review also highlights the technology’s potential beyond COVID-19.